top of page

Can a Gastric Biopsy Miss an Helicobacter pylori Infection? The Research May Surprise You.

Nov 4
6 min read

Updated: 3 days ago

I have previously written about chronic Helicobacter pylori (H. pylori) infection, focusing on its potential association with various skin conditions and research suggesting an increased risk of dementia when this bacterium is chronically present. Today, I want to discuss something different: how accurately are we diagnosing this infection in the first place?


For many years, gastric biopsy performed during an upper endoscopy, also called an EGD, has been regarded as one of the gold standards for diagnosing H. pylori infection. However, after reviewing the medical literature more closely, I have come to question just how reliable a negative gastric biopsy really is.



How Accurate Is a Gastric Biopsy?


Conventional gastric biopsy histology is generally reported to have a sensitivity of approximately 90–95% for detecting H. pylori infection when appropriate sampling and staining techniques are used.


What exactly does sensitivity mean? If a test is 95% sensitive, it means that out of 100 people who actually have the infection or condition, approximately 95 will test positive. The other 5 will have a false-negative result, meaning they have the infection, but the test fails to detect it.


A sensitivity of 90–95% is fairly good. However, this assumes that the test is performed under appropriate conditions. Something I have recently been reviewing is how much the location of a gastric biopsy influences the sensitivity of the test. H. pylori does not necessarily distribute itself evenly throughout the stomach. One area may contain a significant number of bacteria, while another may have relatively few organisms. Consequently, where the gastroenterologist obtains the biopsy matters. Taking biopsies from multiple locations, including the antrum and body of the stomach, improves the likelihood of identifying an infection. The use of special stains can also improve detection, particularly when the number of organisms is low.

But there is another issue that I believe deserves much more attention: proton pump inhibitor medications.



What Happens When Someone Is Taking a PPI?


After encountering several patients who had previously undergone one or more EGDs with negative H. pylori testing, I decided to look more closely at the published research.


Many of these patients had longstanding gastroesophageal reflux disease (GERD) and were taking proton pump inhibitors, or PPIs, for years. These medications include omeprazole (Prilosec), esomeprazole (Nexium), pantoprazole (Protonix), and lansoprazole (Prevacid). PPIs suppress stomach acid production. Although they can be effective at controlling reflux symptoms, they also alter the gastric environment and can reduce the number of H. pylori organisms detectable in biopsy samples. They may also change where the bacteria are distributed within the stomach. This creates an interesting problem.


A patient can have an active H. pylori infection, but the medication being taken for gastrointestinal symptoms may make the infection more difficult to identify. A 2008 study published in the World Journal of Gastroenterology compared gastric biopsy histology with PCR testing in patients taking PPIs and those not taking these medications. The researchers found that histology was 89% sensitive in patients not taking PPIs, but sensitivity decreased to 73% in those taking PPIs. Think about that for a moment. In this study, approximately one out of every four patients with a positive gastric biopsy PCR who was taking a PPI had a negative result on conventional histology.


The researchers also examined PCR testing performed on gastric juice. In patients taking PPIs, gastric juice PCR demonstrated a sensitivity of 86%, compared with 73% for histology. This suggests that molecular testing may identify infections that conventional biopsy histology misses, particularly when patients are taking acid-suppressing medication.


However, I found another study that was even more interesting.



A 2018 Study Compared Gastric Biopsy Histology With PCR Testing


In 2018, researchers published a study in the United European Gastroenterology Journal comparing several methods of detecting H. pylori, including conventional histology, immunohistochemical staining, bacterial culture, and PCR testing. Before discussing the results, I want to explain PCR testing because it is important to understand why the results may differ so dramatically.


What Is PCR Testing?


PCR stands for polymerase chain reaction. This is a molecular laboratory technique that amplifies targeted segments of genetic material, making it possible to detect very small quantities of DNA from an organism. For H. pylori, PCR testing looks for specific bacterial DNA sequences. One of the advantages of PCR is that it does not require the laboratory to visually identify bacteria under a microscope. Even when very few organisms are present in a tissue sample, bacterial DNA may still be detectable. PCR can be extremely sensitive, although the actual sensitivity depends on the specific assay, the specimen collected, and how the test was performed. It is not accurate to assume that every PCR test is 100% sensitive.


There is also an important limitation. PCR detects genetic material, which does not necessarily mean that living bacteria are present. Following treatment, bacterial DNA may remain detectable for a period of time even after the infection has been successfully eradicated. (We all saw this during the pandemic when for weeks after the infection, home PCR tests continued to be positive.) For this reason, PCR testing must be interpreted in the appropriate clinical context, especially when it is being used to determine whether treatment was successful.

Currently, PCR testing for H. pylori is easily available through Diagnostic Solutions and tests a patient's stool for H. pylori.  The blog author is only aware of one lab that performs PCR testing of gastric biospy.
Currently, PCR testing for H. pylori is easily available through Diagnostic Solutions and tests a patient's stool for H. pylori. The blog author is only aware of one lab that performs PCR testing of gastric biospy.

Back to the Study, Here Is Where Things Get Interesting


The 2018 investigators evaluated 497 patients, of whom 192 were included in the analysis of diagnostic sensitivity according to PPI use. Of those 192 patients, 52 had taken a PPI during the preceding 14 days, and 140 had not. PCR testing of gastric biopsy tissue was used as the reference standard. The investigators then evaluated how often conventional histology identified the infections detected by PCR.


The results were striking. In patients who were not taking PPIs, gastric biopsy histology demonstrated a sensitivity of only 50%. In those who had taken PPIs, the sensitivity was even lower, at 30%. Let me put this into perspective. Among the 32 patients not taking PPIs who tested positive by gastric biopsy PCR, conventional histology identified only 16. That means 16 patients had negative histology despite positive PCR testing. Among the 20 patients taking PPIs who tested positive by PCR, histology identified only six. The remaining 14 had negative histology. In other words, histology missed 70% of the PCR-positive cases in the PPI group. These findings are substantially different from the commonly cited 90–95% sensitivity of conventional gastric biopsy histology.


It is important to recognize that the study was relatively small when divided into these groups. Although sensitivity was numerically lower among PPI users, this difference was not statistically significant. The researchers did, however, find that PCR detected significantly more infections than histology in both groups.

Also, because PCR was used as the reference standard, the study does not establish that gastric histology is only 30–50% sensitive in every clinical setting.

Nevertheless, these findings raise an important question about the reliability of conventional histology, particularly when the result is negative.



Does This Mean PCR Is the New Gold Standard?


In both of the studys, they were evaluating PCR performed on gastric biopsy tissue or gastric juice, not stool PCR. Unfortunately, this form of PCR testing is not readily available at labs analyzing gastric biopsy from endoscopy. PCR testing is expensive and when payers (insurance, Medicare, etc.) do not pay for it, it is not available or offered.


There is also no single perfect test for H. pylori infection. Conventional histology, PCR, stool antigen testing, and urea breath testing each have advantages and limitations.

Sample report stool antigen testing H. pylori.
Stool antigen testing for H. pylori, which is not a PCR test, has reduced sensitivity when PPI medications (and others) are taken within 2 weeks of testing.

A biopsy also provides information that PCR alone cannot, such as the presence of gastric inflammation, intestinal metaplasia, or other abnormalities in the stomach lining. Therefore, molecular testing does not replace the other reasons a physician may recommend an EGD. However, when the specific question is whether H. pylori is present, I believe PCR deserves consideration, especially in patients with a high clinical suspicion of infection and previously negative histology or other tests for the presense of H. pylori.



My Final Thoughts


The more I review the research concerning chronic H. pylori infection, the more I believe that we need to pay attention not only to which test was performed, but also to the circumstances under which it was performed. In patients not taking proton pump inhibitors (PPIs), gastric biopsy histology appeared to have a sensitivity of 89% compared with the PCR technology available in 2008. By 2018, the sensitivity of gastric biopsy histology had declined to 50% compared with PCR.


When a test result for is negative for H. pylori infection and clinical suspicion remains, repeat testing or testing by other methods should be considered. A negative gastric biopsy should not automatically be considered definitive evidence that H. pylori infection is absent, particularly in a patient with ongoing clinical suspicion who was taking a PPI at the time of testing.


References:

  1. Yakoob J, et al. Gastric juice for the diagnosis of H. pylori infection in patients on proton pump inhibitors. World Journal of Gastroenterology. 2008;14(10):1539–1543.https://pmc.ncbi.nlm.nih.gov/articles/PMC2693748/

  2. Bazin T, et al. Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors. United European Gastroenterology Journal. 2018;6(8):1267–1273.https://pmc.ncbi.nlm.nih.gov/articles/PMC6169049/

  3. Chey WD, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology. 2024;119(9):1730–1753.https://doi.org/10.14309/ajg.0000000000002968


Comments


bottom of page